Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

154
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
154
Continuous Renal Replacement Therapy01:30

Continuous Renal Replacement Therapy

488
Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...
488
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

339
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
339
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

476
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
476
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

135
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
135
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy01:26

Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy

90
Continuous Renal Replacement Therapy (CRRT) is an essential intervention for patients experiencing severe kidney dysfunction. This therapy offers a continuous mechanism for removing fluids and toxins from the bloodstream, leveraging the patient’s blood pressure to facilitate filtration through a specialized filter. This method contrasts with intermittent dialysis, providing a gentler and more consistent removal of waste products and excess fluid, which is particularly beneficial in...
90

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Alpha2 agonists for sedation to produce better outcomes for adults with critical illness: a synopsis of the A2B RCT with cost-effectiveness and process evaluation.

Health technology assessment (Winchester, England)·2026
Same author

Publisher Correction: Metabolic septic shock sub-phenotypes, stability over time and association with clinical outcome.

Intensive care medicine·2026
Same author

Ivermectin for Critically and Noncritically Ill Hospitalized Patients With COVID-19: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP).

Critical care medicine·2026
Same author

Improving retrospective ARDS case-finding using a simple 72-h physiologic persistence rule.

Intensive care medicine experimental·2026
Same author

Intermediate dose heparin thromboprophylaxis among critically ill patients with COVID-19: a randomized clinical trial.

Journal of thrombosis and haemostasis : JTH·2026
Same author

Bedside identification of subphenotypes in acute respiratory failure (PHIND): a multicentre, observational cohort study.

The Lancet. Respiratory medicine·2026

Related Experiment Video

Updated: Dec 11, 2025

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.5K

Vasopressor Therapy in the Intensive Care Unit.

James A Russell1,2, Anthony C Gordon3,4, Mark D Williams5

  • 1Department of Medicine, Centre for Heart Lung Innovation, St. Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada.

Seminars in Respiratory and Critical Care Medicine
|August 22, 2020
PubMed
Summary

Vasopressors are crucial for treating vasodilatory shock but lack RCTs showing reduced mortality. Research is needed for alternative first-line vasopressors to improve patient outcomes and minimize adverse effects.

More Related Videos

Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema
08:44

Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema

Published on: September 1, 2016

9.2K
Non-Invasive Monitoring of Microvascular Oxygenation and Reactive Hyperemia using Hybrid, Near-Infrared Diffuse Optical Spectroscopy for Critical Care
14:28

Non-Invasive Monitoring of Microvascular Oxygenation and Reactive Hyperemia using Hybrid, Near-Infrared Diffuse Optical Spectroscopy for Critical Care

Published on: May 10, 2024

2.0K

Related Experiment Videos

Last Updated: Dec 11, 2025

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.5K
Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema
08:44

Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema

Published on: September 1, 2016

9.2K
Non-Invasive Monitoring of Microvascular Oxygenation and Reactive Hyperemia using Hybrid, Near-Infrared Diffuse Optical Spectroscopy for Critical Care
14:28

Non-Invasive Monitoring of Microvascular Oxygenation and Reactive Hyperemia using Hybrid, Near-Infrared Diffuse Optical Spectroscopy for Critical Care

Published on: May 10, 2024

2.0K

Area of Science:

  • Critical Care Medicine
  • Pharmacology
  • Emergency Medicine

Background:

  • Vasodilatory shock, including septic shock, requires vasopressor therapy after fluid administration.
  • Current vasopressors target adrenergic, angiotensin II, vasopressin, and dopamine receptors.
  • Significant heterogeneity exists in vasopressor selection and dosing, leading to variable outcomes and adverse effects like organ ischemia and arrhythmias.

Purpose of the Study:

  • To review the current evidence and clinical practice of vasopressor use in vasodilatory shock.
  • To highlight the need for alternative first-line vasopressors and novel therapeutic strategies.
  • To discuss the limitations of existing vasopressors and potential future directions in treatment.

Main Methods:

  • Review of existing literature on vasopressor use in vasodilatory shock.
  • Analysis of vasopressor mechanisms of action, receptor targets, and adverse effects.
  • Discussion of current clinical guidelines and emerging therapeutic approaches.

Main Results:

  • No randomized controlled trial (RCT) has demonstrated a decrease in 28-day mortality with vasopressor use.
  • Norepinephrine is the current first-choice vasopressor for septic and vasodilatory shock.
  • Interventions like vasopressin and angiotensin II have not significantly reduced mortality; dopamine use is declining due to adverse effects.

Conclusions:

  • There is a critical need for evidence-based alternative first-line vasopressors for vasodilatory shock.
  • Future strategies may involve combination therapy, biomarker-guided selection, and development of novel vasopressors with improved safety profiles.
  • Optimizing vasopressor therapy requires addressing heterogeneity in patient populations and physician practices to minimize adverse events and improve survival rates.